PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34289988-0	2021	Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR tyrosine kinase inhibitor, osimertinib.	osimertinib	131-142	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	10-15	
34289988-4	2021	Consequently, we have identified a novel connection between osimertinib or other EGFR TKI and c-Myc.	osimertinib	60-71	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	94-99	
34289988-5	2021	Osimertinib rapidly and sustainably decreased c-Myc levels primarily via enhancing protein degradation in EGFR-mutant (EGFRm) NSCLC cell lines and xenograft tumors.	osimertinib	0-11	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	46-51	
34289988-6	2021	c-Myc levels were substantially elevated in different EGFRm NSCLC cell lines with acquired resistance to osimertinib in comparison with their corresponding parental cell lines and could not be reduced any further by osimertinib.	osimertinib	216-227	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-5	
34289988-8	2021	Suppression of c-Myc through knockdown or pharmacological targeting with BET inhibitors restored the response of resistant cell lines to osimertinib.	osimertinib	137-148	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	15-20	
34289988-9	2021	These findings indicate that c-Myc modulation mediates the therapeutic efficacy of osimertinib and the development of osimertinib-acquired resistance.	osimertinib	83-94	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	29-34	
34289988-9	2021	These findings indicate that c-Myc modulation mediates the therapeutic efficacy of osimertinib and the development of osimertinib-acquired resistance.	osimertinib	118-129	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	29-34